Sanguine Corp. (fka SGUI)

[manny21]

Posted on: Tuesday, 7 February 2006, 06:00 CST
Sanguine Evaluates a New Science Approach to Use PHER-O2 in Conjunction With Type 2 Diabetes Therapies
Sanguine Corp. (OTCBB: SGNC), a bio-pharmaceutical company focused on the development of oxygen-carrying synthetic substitutes for human red blood cells and numerous other areas requiring oxygen perfusion, was presented a new scientific approach by an international medical group whereby PHER-O2 would be used to increase oxygenation to the small vessels that supply blood to critical areas of the body affected by Type 2 diabetes. Dr. Robert Kwun, a board-certified surgeon, is evaluating the science for the Sanguine medical team.

Kwun remarked, "The Sanguine product, PHER-O2, has long been viewed by us as a blood substitute. However, when considering the oxygen-carrying capacity associated with the product's predecessor, FDA-approved Fluosol, it's reasonable that PHER-O2 could be beneficial to many medical situations where increased oxygen into the microvascular system is desired. In addition to the Edmonton protocol and PHER-O2 work, which are for type 1 diabetics, it follows that efforts to evaluate science, which could aid type 2 diabetics directly, compliments the company's expanded business direction involving diabetes therapies. I look forward to evaluating this science to determine if PHER-O2 can play a role."

Dr. Thomas C. Drees, Ph.D., president and CEO, added, "The worldwide market for diabetic therapies, both type 1 and type 2, is huge. According to industry sources, the diabetes market is believed to top 10 billion dollars annually and growing. We are anxious and happy to consider any science where PHER-O2 may play a beneficial role in diabetic medical therapies. Our team looks forward to Dr. Kwun's findings."

For information related to the Sanguine Corp., contact Investor Relations: Michael Dancy, 801-746-3570, e-mail: [e-mail], or visit: www.sanguine-corp.com.